Autolus Therapeutics (NASDAQ:AUTL) Receives “Buy” Rating from Needham & Company LLC

Autolus Therapeutics (NASDAQ:AUTLGet Free Report)‘s stock had its “buy” rating reissued by investment analysts at Needham & Company LLC in a note issued to investors on Monday,Benzinga reports. They presently have a $10.00 price objective on the stock. Needham & Company LLC’s price target points to a potential upside of 352.49% from the stock’s previous close.

AUTL has been the subject of a number of other research reports. The Goldman Sachs Group raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $7.00 to $7.60 in a report on Monday, November 18th. Redburn Atlantic upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective on the stock in a report on Friday, November 15th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Autolus Therapeutics has an average rating of “Buy” and an average target price of $10.40.

Check Out Our Latest Research Report on Autolus Therapeutics

Autolus Therapeutics Stock Performance

Shares of AUTL stock opened at $2.21 on Monday. Autolus Therapeutics has a 52 week low of $2.07 and a 52 week high of $7.37. The firm’s 50-day simple moving average is $2.81 and its two-hundred day simple moving average is $3.59. The firm has a market cap of $588.07 million, a price-to-earnings ratio of -1.83 and a beta of 2.05.

Autolus Therapeutics (NASDAQ:AUTLGet Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same quarter in the prior year, the company earned ($0.26) EPS. Analysts forecast that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in AUTL. ProShare Advisors LLC purchased a new stake in Autolus Therapeutics during the second quarter valued at $43,000. Capstone Investment Advisors LLC bought a new stake in shares of Autolus Therapeutics during the 3rd quarter valued at about $51,000. Daiwa Securities Group Inc. increased its position in shares of Autolus Therapeutics by 2,659.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock valued at $55,000 after purchasing an additional 15,293 shares during the last quarter. Herbst Group LLC bought a new position in shares of Autolus Therapeutics in the 3rd quarter worth approximately $91,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Autolus Therapeutics by 63.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company’s stock worth $139,000 after buying an additional 14,959 shares during the last quarter. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

(Get Free Report)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.

Featured Articles

Analyst Recommendations for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.